Common Variable Immunodeficiency Support Group
Common variable immunodeficiency (CVID) is a group of 20-30 primary immunodeficiencies (PIDs) which have a common set of symptoms but with different underlying causes. CVID's underlying causes are different, but the result of these are that the body doesn't produce sufficient antibodies in response to exposure to pathogens.
PI (2.1) 300-600 mg/kg Every 3 to 4 weeks...this is how I find it written everywhere...except I have no idea how to calculate that to grams LOL I'm sorry I suck...I know someone on here would :) I know Mark takes like 80grams every 4 weeks...sorry dangit I wish I knew grrrr
The amount you were getting before does sound very low. I am 5' 3", and 125 and started out on 22 grams of Gammagard S/D. Since then it was reduced to 20 grams because there was waste involved with the original amount (5 grams is the lowest increment I guess).
This amount was originally figured out based on my weight according to my doctor, but he also doesn't seem to be concerned at all about how I feel at that amount. He is only concerned on whether or not I stay at trough levels of over 600.
Good luck with your new dosage, and I hope that it makes you feel much better!
does being on antibiotics affect the infusion? i hope not, unless its a good affect! i go on vacation august 1 & i don't want to miss it, or be sick/fatigued the whole time
of administration
After deficient antibody production has been documented,
infusions are usually given every 3 to 4 weeks at
an initial dose of 0.4 to 0.6 g/kg, titrating the dose and
interval between infusions to achieve a trough IgG level at
least greater than 500 mg/dL in agammaglobulinemic
patients.46 Many practitioners target a serum IgG level
equal to the pretreatment level plus 300 mg/dL for patients
with CVID. A specific maintenance of trough level greater
than 500 mg/dL has been associated with fewer infections
and improved outcomes.10,18,47 Higher trough levels
(>800 mg/dL) also have the potential to improve pulmonary
outcome.10,48 Monitoring preinfusion trough levels
at no greater than 3-month intervals, and preferably no
greater than every 6 months, might be helpful in patients
who are hypogammaglobulinemic, particularly when infections
are not well controlled. Because there is significant
variability among patients in the pharmacokinetics
of IgG, a given IGIV dose has the potential to result in different
trough levels in different patients having similar
body mass.49 An acceptable starting point for maintenance
dosing is 0.4 g/kg every 3 to 4 weeks. Although some
clinicians measure trough IgG levels frequently, others
measure serum IgG levels annually or whenever there is
a significant infection and when the clinical response to
treatment does not meet expectations. After the sixth infusion,
a steady state will have been achieved, and the dose
or dosing interval should be adjusted to achieve the optimal
clinical result. Trough IgG levels should be considered
in optimizing therapy for agammaglobulinemic and
potentially hypogammaglobulinemic patients. Treating
physicians must be mindful of patients changing body
mass (particularly children and pregnant patients), the possibility
of protein-losing conditions, or both, and dose
adjustments need to be made accordingly. When initiating
therapy, patients with extremely low IgG levels at presentation
might benefit from a larger loading dose before the
initiation of regular maintenance dosing. Some centers use
an initial dose of 1 g/kg administered slowly for agammaglobulinemic
patients. Other centers prefer smaller doses
given more frequently to initially provide agammaglobulinemic
patients with adequate levels of IgG."
From being part of the PIDD community for the past 30 years, I've concluded that patients treated by an clinical immunologist have far better outcomes than patients treated by an allergist without specif training.